Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Agreement Averts Another Proxy Fight Between Biogen Idec, Icahn

This article was originally published in The Pink Sheet Daily

Executive Summary

Despite agreeing to support Biogen's nominee slate, Icahn says he still will push for biotech sale.

You may also be interested in...



BMS M&A Q&A: Is IO Player Now In Play? Lung Cancer Moves Seen As Key

Will activist investors succeed in unlocking Bristol-Myers Squibb's shareholder value - or instead orchestrate a takeover worth more than $100bn?

Biogen's New EVP Commercial Ops Tony Kingsley: An Interview With "The Pink Sheet" DAILY

Execution, discipline, and reliance on proven sales and marketing methods helped turn around key multiple sclerosis drug Avonex, says Biogen's new EVP, Global Commercial Operations.

Biogen's New EVP Commercial Ops Tony Kingsley: An Interview With "The Pink Sheet" DAILY

Execution, discipline, and reliance on proven sales and marketing methods helped turn around key multiple sclerosis drug Avonex, says Biogen's new EVP, Global Commercial Operations.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS070384

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel